乳腺癌易感基因2相关蛋白抗体

乳腺癌易感基因2相关蛋白抗体英文名称  Anti-BRAF35 

中文名称  乳腺癌易感基因2相关蛋白抗体 

别    名  BRAF25; BRAF35; BRCA 2 Associated Factor (35kDa); BRCA2 associated factor 35; BRCA2-associated factor 35; High Mobility Group Protein 20B; HM20B_HUMAN; HMG 20B; HMG box containing protein 20B; HMG box-containing protein 20B; HMG domain-containing protein 2; HMG domain-containing protein HMGX2; hmg20b; HMGX2; PP7706; pp8857; SMARCE1 related protein; SMARCE1-related protein; SMARCE1r; sox like; Sox like transcriptional factor; Sox-like transcriptional factor; SOXL; Structural DNA binding protein BRAF35; Structural DNA-binding protein BRAF35; SWI/SNF related; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related. 

浓    度  1mg/1ml 

规 格  0.2ml/200μg 

抗体来源  Rabbit  

克隆类型  polyclonal 

交叉反应  Human, Mouse, Rat, Cow  

产品类型  一抗    

研究领域  肿瘤 细胞生物 转录调节因子  

蛋白分子量  predicted molecular weight: 36kDa 

性    状  Lyophilized or Liquid 

免 疫 原  KLH conjugated synthetic peptide derived from human BRAF35 

亚    型  IgG 

纯化方法  affinity purified by Protein A 

储 存 液  Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4 

产品应用   WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500 

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

乳腺癌易感基因2相关蛋白抗体产品介绍 The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

Function : Required for correct progression through G2 phase of the cell cycle and entry into mitosis. Required for RCOR1/CoREST mediated repression of neuronal specific gene promoters.

Subunit : Component of a BHC histone deacetylase complex thatcontains HDAC1, HDAC2, HMG20B/BRAF35, KDM1A, RCOR1/CoREST andPHF21A/BHC80. The BHC complex may also contain ZMYM2, ZNF217,ZMYM3, GSE1 and GTF2I. Interacts with the BRCA2 tumor suppressorprotein.

Subcellular Location : Nucleus. Chromosome. Localized to condensed chromosomes in mitosis in conjunction with BRCA2.

Tissue Specificity : Ubiquitously expressed in adult tissues.

Similarity : Contains 1 HMG box DNA-binding domain.

Database links : UniProtKB/Swiss-Prot: Q9P0W2.1